BIIB 250502 122.00P(BIIB250502P122000) Stock Price Today | Quotes & News - Moomoo

US OptionsDetailed Quotes

BIIB250502P122000

Watchlist

0.15
-0.97-86.61%

15min DelayClose May 2 16:00 ET

0.15High0.15Low

Intraday

5D
Daily

News

Biogen Emerging as 'Leaner, Less Risky' Company, RBC Says
MT NewswiresMay 2 11:58 ET
Biogen Is Maintained at Buy by Canaccord Genuity
Dow JonesMay 2 11:49 ET · Ratings
Biogen Price Target Cut to $220.00/Share From $265.00 by Canaccord Genuity
Dow JonesMay 2 11:49 ET · Ratings
Canaccord Genuity Adjusts Price Target on Biogen to $220 From $265
MT NewswiresMay 2 11:08 ET · Ratings
HC Wainwright & Co. Maintains Buy on Biogen, Lowers Price Target to $187
BenzingaMay 2 09:16 ET · Ratings
A Quick Look at Today's Ratings for Biogen(BIIB.US), With a Forecast Between $144 to $220
Moomoo NewsMay 2 09:00 ET · Ratings

Comments

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

$Biogen (BIIB.US)$
Breakthrough: First-Ever Drug to Slow Early Alzheimer's Gets EU Green Light

Leqembi®∇ (lecanemab) is the First Medicine that Slows Progression of Early Alzheimer’s Disease to be Authorized in the European Union

1

Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

$Organon & Co (OGN.US)$ $Biogen (BIIB.US)$
Organon Claims US Market Leadership with Groundbreaking Tocilizumab Biosimilar Deal

Organon Acquires TOFIDENCE™ (tocilizumab-bavi), a Commercialized Biosimilar to ACTEMRA® (tocilizumab) Injection, for Intravenous Infusion in the U.S.

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

$Biogen (BIIB.US)$
Biogen's Bold Move: 580,000 sq ft Innovation Powerhouse to Transform Kendall Square Research Hub

Biogen Announces Plans for New Global Headquarters and Innovation Hub in Kendall Square

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

$Biogen (BIIB.US)$
Biogen's Breakthrough Drug Enters Final Testing Phase for Critical Kidney Transplant Complication

Biogen Initiates Phase 3 Study of Felzartamab for the Treatment of Late Antibody-Mediated Rejection (AMR) in Kidney Transplant Patients

confirmed bottom

$Biogen (BIIB.US)$ confirmed technical bottom

Read more